S&P 500   4,451.22 (+0.05%)
DOW   34,771.35 (+0.02%)
QQQ   371.85 (-0.30%)
AAPL   146.34 (-0.33%)
MSFT   297.33 (-0.74%)
FB   351.85 (+1.70%)
GOOGL   2,835.74 (+0.40%)
TSLA   762.00 (+1.11%)
AMZN   3,405.05 (-0.32%)
NVDA   219.48 (-2.38%)
BABA   145.72 (-3.62%)
NIO   35.50 (-1.42%)
CGC   13.99 (-3.91%)
GE   103.62 (+0.64%)
MU   74.20 (+0.22%)
AMD   105.33 (-0.77%)
T   27.21 (+0.07%)
F   13.85 (+1.02%)
ACB   6.05 (-1.63%)
DIS   175.68 (-0.32%)
PFE   43.98 (-0.48%)
BA   221.73 (+0.28%)
BAC   42.30 (+1.46%)
S&P 500   4,451.22 (+0.05%)
DOW   34,771.35 (+0.02%)
QQQ   371.85 (-0.30%)
AAPL   146.34 (-0.33%)
MSFT   297.33 (-0.74%)
FB   351.85 (+1.70%)
GOOGL   2,835.74 (+0.40%)
TSLA   762.00 (+1.11%)
AMZN   3,405.05 (-0.32%)
NVDA   219.48 (-2.38%)
BABA   145.72 (-3.62%)
NIO   35.50 (-1.42%)
CGC   13.99 (-3.91%)
GE   103.62 (+0.64%)
MU   74.20 (+0.22%)
AMD   105.33 (-0.77%)
T   27.21 (+0.07%)
F   13.85 (+1.02%)
ACB   6.05 (-1.63%)
DIS   175.68 (-0.32%)
PFE   43.98 (-0.48%)
BA   221.73 (+0.28%)
BAC   42.30 (+1.46%)
S&P 500   4,451.22 (+0.05%)
DOW   34,771.35 (+0.02%)
QQQ   371.85 (-0.30%)
AAPL   146.34 (-0.33%)
MSFT   297.33 (-0.74%)
FB   351.85 (+1.70%)
GOOGL   2,835.74 (+0.40%)
TSLA   762.00 (+1.11%)
AMZN   3,405.05 (-0.32%)
NVDA   219.48 (-2.38%)
BABA   145.72 (-3.62%)
NIO   35.50 (-1.42%)
CGC   13.99 (-3.91%)
GE   103.62 (+0.64%)
MU   74.20 (+0.22%)
AMD   105.33 (-0.77%)
T   27.21 (+0.07%)
F   13.85 (+1.02%)
ACB   6.05 (-1.63%)
DIS   175.68 (-0.32%)
PFE   43.98 (-0.48%)
BA   221.73 (+0.28%)
BAC   42.30 (+1.46%)
S&P 500   4,451.22 (+0.05%)
DOW   34,771.35 (+0.02%)
QQQ   371.85 (-0.30%)
AAPL   146.34 (-0.33%)
MSFT   297.33 (-0.74%)
FB   351.85 (+1.70%)
GOOGL   2,835.74 (+0.40%)
TSLA   762.00 (+1.11%)
AMZN   3,405.05 (-0.32%)
NVDA   219.48 (-2.38%)
BABA   145.72 (-3.62%)
NIO   35.50 (-1.42%)
CGC   13.99 (-3.91%)
GE   103.62 (+0.64%)
MU   74.20 (+0.22%)
AMD   105.33 (-0.77%)
T   27.21 (+0.07%)
F   13.85 (+1.02%)
ACB   6.05 (-1.63%)
DIS   175.68 (-0.32%)
PFE   43.98 (-0.48%)
BA   221.73 (+0.28%)
BAC   42.30 (+1.46%)
ASX:PME

Pro Medicus Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume285,954 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.27%
BetaN/A

Receive PME News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro Medicus and its competitors with MarketBeat's FREE daily newsletter.


About Pro Medicus

Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.10 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pro Medicus (ASX:PME) Frequently Asked Questions

What stocks does MarketBeat like better than Pro Medicus?

Wall Street analysts have given Pro Medicus a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pro Medicus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How often does Pro Medicus pay dividends? What is the dividend yield for Pro Medicus?

Pro Medicus announced a Final dividend on Thursday, August 19th. Investors of record on Thursday, September 30th will be given a dividend of 0.08 per share on Thursday, September 30th. This represents a yield of 0.12%. The ex-dividend date is Wednesday, September 8th. This is an increase from Pro Medicus's previous Final dividend of A$0.06.
View Pro Medicus' dividend history
.

Is Pro Medicus a good dividend stock?

Pro Medicus pays an annual dividend of A$0.16 per share and currently has a dividend yield of 0.27%. The dividend payout ratio of Pro Medicus is 54.24%. This payout ratio is at a healthy, sustainable level, below 75%.
View Pro Medicus' dividend history.

Who are Pro Medicus' key executives?

Pro Medicus' management team includes the following people:
  • Dr. Sam Aaron Hupert M.D., M.B.B.S., Co-Founder, CEO, MD & Exec. Director
  • Mr. Anthony Barry Hall B.Sc., B.Sc.(Hons), M.Sc., Co-Founder, Technology Director & Exec. Director
  • Dr. Malte Westerhoff, GM of Europe & Global CTO
  • Mr. Brad Levin, GM of North America & Global Head of Marketing
  • Mr. Sean Lambright, Global Head of Sales - Visage Imaging Inc
  • Mr. Clayton James Hatch CPA, B.Comm, CPA, CFO & Company Sec.

What other stocks do shareholders of Pro Medicus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pro Medicus investors own include ImmuPharma (IMM), Blackmores (BKL), Bank of America (BAC), The Boeing (BA), Accent Group (AX1), Axos Financial (AX), ARB (ARB), Appen (APX), Arista Networks (ANET) and Altium (ALU).

What is Pro Medicus' stock symbol?

Pro Medicus trades on the ASX under the ticker symbol "PME."

How much money does Pro Medicus make?

Pro Medicus has a market capitalization of $0.00 and generates $67.88 million in revenue each year.

How many employees does Pro Medicus have?

Pro Medicus employs 2,060 workers across the globe.

What is Pro Medicus' official website?

The official website for Pro Medicus is www.promed.com.au.

How can I contact Pro Medicus?

The company can be reached via phone at 61 3 9429 8800.


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.